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Shekhawat, Prem, Michael J. Bennett, Yoel Sa-
dovsky, D. Michael Nelson, Dinesh Rakheja, and Ar-
nold W. Strauss. Human placenta metabolizes fatty acids:
implications for fetal fatty acid oxidation disorders and ma-
ternal liver diseases. Am J Physiol Endocrinol Metab 284:
E1098–E1105, 2003. First published February 11, 2003;
10.1152/ajpendo.00481.2002.—The role of fat metabolism
during human pregnancy and in placental growth and func-
tion is poorly understood. Mitochondrial fatty acid oxidation
disorders in an affected fetus are associated with maternal
diseases of pregnancy, including preeclampsia, acute fatty
liver of pregnancy, and the hemolysis, elevated liver en-
zymes, and low platelets syndrome called HELLP. We have
investigated the developmental expression and activity of six
fatty acid -oxidation enzymes at various gestational-age
human placentas. Placental specimens exhibited abundant
expression of all six enzymes, as assessed by immunohisto-
chemical and immunoblot analyses, with greater staining in
syncytiotrophoblasts compared with other placental cell
types. -Oxidation enzyme activities in placental tissues
were higher early in gestation and lower near term. Tropho-
blast cells in culture oxidized tritium-labeled palmitate and
myristate in substantial amounts, indicating that the human
placenta utilizes fatty acids as a signiﬁcant metabolic fuel.
Thus human placenta derives energy from fatty acid oxida-
tion, providing a potential explanation for the association of
fetal fatty acid oxidation disorders with maternal liver dis-
eases in pregnancy.
acute fatty liver of pregnancy; mitochondria; hemolysis, ele-
vated liver enzymes, and low platelets syndrome
BECAUSE THE PLACENTA PROVIDES THE FETUS with nutrients
needed for growth and serves as an excretory organ to
eliminate wastes from fetal metabolism, placental pa-
thology profoundly affects the developing fetus. The
placenta grows exponentially during gestation, from
an average of6ga t3w ko fgestation to 470 g at term.
Moreover, the villous surface increases from 830 cm2 at
3 wk of gestation to 125,000 cm2 at term, and the
maternal-fetal diffusion distance decreases from 55 to
4.8 mm (16). The placenta requires a constant and
abundant source of energy to supply the needs for its
own rapid growth and maturation and to transport the
nutrients, ions, vitamins, waste, and other molecules
required for fetal growth and homeostasis from the
maternal to the fetal circulation and vice versa.
A common belief among fetal physiologists (14, 16,
18, 20, 26) is that glucose transported to and across the
placenta from the maternal circulation provides all
placental and fetal energy needs via glycolysis and the
citric acid cycle. Because this supply of glucose is con-
stant, consistent, and reliable, it has been suggested
that the placenta and fetus do not need to regulate
energy-producing metabolic pathways. The focus of
most research has been on transplacental passage of
nutrients, including both amino acids and fatty acids,
but the metabolic fuel required by the human placenta
has not been determined conclusively. The presence of
multiple glucose transporters and enzymes of glycoly-
sis and the citric acid cycle in the placenta is consistent
with glucose being a major energy source (14). It has
been postulated that adequate glucose supply, conver-
sion of acetyl-CoA to malonyl-CoA by acetyl-CoA car-
boxylase, and the resultant inhibition of carnitine
palmitoyltransferase I (CPT I) (26) inhibit fatty acid
uptake and oxidation by placental mitochondria in
utero (20). Although fatty acids are actively trans-
ported across the placenta to the fetus, there are scant
data to assess the role of lipids as a metabolic fuel for
placental growth and development (18).
Fatty acid oxidation (FAO) defects are autosomal
recessive and potentially fatal disorders that are now
diagnosed with increased frequency in the perinatal
and infantile periods. Uniquely among inherited met-
abolic defects, FAO enzyme disorders in the affected
fetus may cause signiﬁcant maternal morbidity and
mortality (11, 13, 15, 23, 27, 32, 33, 39). We (11, 13, 23)
and others (15, 27, 32, 33, 39) have recently shown that
maternal acute fatty liver of pregnancy (AFLP), the
HELLP syndrome (hemolysis, elevated liver enzymes,
and low platelets), placental ﬂoor infarction, and pre-
eclampsia are associated with defects in FAO in the
fetus. The majority of neonates born after such preg-
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present in the newborn period or early infancy with
fasting-induced hypoketotic hypoglycemia and hepatic
encephalopathy, which may progress to coma and
death (11, 33).
Because FAO disorders in the fetus are associated
with maternal complications and because the human
placenta is mostly of fetal origin, we hypothesized that
energy supplied from fatty acid -oxidation in the pla-
centa could be an important metabolic energy source
for survival, growth, and function in both the placenta
and the fetus. As a corollary, if FAO were active in the
placenta and because late-gestation placenta is of fetal
origin, fetal defects in this pathway would generate
long-chain fatty acids that could enter the maternal
circulation in levels toxic to the mother. We report here
the developmental expression and activity of six differ-
ent FAO enzymes of the mitochondrial -oxidation
spiral in human placenta (Fig. 1): medium-chain acyl-
CoA dehydrogenase (MCAD), long-chain acyl-CoA de-
hydrogenase (LCAD), very-long-chain acyl-CoA dehy-
drogenase (VLCAD), short-chain L-3-hydroxyacyl-CoA
dehydrogenase (SCHAD), long-chain L-3-hydroxyacyl-
CoA dehydrogenase (LCHAD), and long-chain 3-keto-
acyl-CoA thiolase (LKAT). We used immunohistochem-
istry, Western blot analysis, enzyme activity measure-
ments, and metabolic ﬂux studies to demonstrate
substantial FAO expression and function of these en-
zymes in the human placenta, consistent with our
hypotheses.
METHODS
Placental tissues and cells. This study was approved by the
Human Studies Committee of Washington University School
of Medicine. Placental specimens were collected at gesta-
tional ages ranging from 12 to 43 wk. Tissue was placed in
chilled, buffered saline to remove maternal blood and then
snap-frozen in liquid nitrogen and stored at 80°Co rﬁxed in
10% neutral buffered formalin solution at 4°C for 24 h before
being processed for parafﬁn embedding and immunohisto-
chemical studies. Twenty-eight placental specimens were
used for enzyme activity and Western blot studies. Speci-
mens were divided for analysis into the following gestational
age groups: 12–19 (n  3), 20–28 (n  3), 29–34 (n  5),
35–37 (n  4), 38 wk (n  9), and 40 wk (n  4). All samples
were utilized to measure enzyme activity, and nine of these
samples from 12 to 43 wk of gestation were used to run
Western blots for the six FAO enzymes.
For enzyme activity and metabolic ﬂux studies, primary
human cytotrophoblasts were isolated from normal-term hu-
man placentas (n  4) by use of the trypsin-DNAse-dispase/
Percoll method, as described (25). Cultures were plated at a
density of 350,000 cells/cm2 and maintained in Earle’sm e -
dium 199 (M199) containing fetal bovine serum, 20 mM
HEPES, pH 7.4, 0.5 mM L-glutamine, penicillin (10 U/ml),
streptomycin (10 mg/ml), and fungizone (0.25 mg/ml). All
cultures were maintained at 37°Ci na5 %C O 2 atmosphere,
and the medium was changed every 24 h. Our trophoblast
cell isolates were 95–97% cytokeratin positive, which indi-
cates that they were trophoblast cells (25).
Immunohistochemistry. Term placentas from uncompli-
cated pregnancies were collected, and 5-m-thick sections of
parafﬁn-embedded tissue were cut, applied to glass slides,
deparafﬁnized in xylene, and rehydrated in an ethanol gra-
dient. Endogenous peroxidase activity was quenched by in-
cubating the specimens in 3% H2O2 in methanol for 30 min.
After equilibration for 5 min in distilled water, the samples
were subjected to heat antigen retrieval using citrate buffer
(pH 6.0). The samples were heated at maximum power in a
microwave for 5 min, cooled for 5 min, reheated for 5 min,
and allowed to stand at room temperature for 20 min.
The slides were then washed and blocked using an avidin-
biotin blocking kit (Vector Labs, Burlingame, CA) for 30 min
Fig. 1. The mitochondrial fatty acid oxida-
tion (FAO) pathway. This schematic repre-
sentation shows the uptake of fatty acids
and carnitine into the placental cell, trans-
fer of fatty acid from the cytosol into mito-
chondria, and the fatty acid -oxidation
spiral. See key for deﬁnitions of terms. Me-
dium- and short-chain fatty acids are
transported directly into the cytosol, but
long-chain fatty acids and carnitine are
transported by speciﬁc plasma membrane
transporters [fatty acid transporter (FAT),
fatty acid-binding protein (FABP)]. Fatty
acids utilize carnitine acyltransferases
CPT I and II and CT to enter mitochondria.
The initial step in the FAO spiral (labeled
1) is the acyl-CoA dehydrogenase reaction
that is catalyzed by the homologous en-
zymes MCAD, LCAD, and VLCAD and
leads to formation of 2,3-enoyl-acyl-CoA.
The second step (labeled 2) is conversion of
of 2,3-enoyl-acyl-CoA to 3-hydroxyacyl-CoA
catalyzed by 2,3-enoyl-CoA hydratase. The
3rd step of the spiral (labeled 3) is conver-
sion of 3-hydroxyacyl-CoA to 3-ketoacyl-
CoA catalyzed by the 2 homologous en-
zymes SCHAD and LCHAD, and the ﬁnal
step (labeled 4) is removal of an acetyl-CoA
from 3-ketoacyl-CoA by the 2 homologous
enzymes SKAT and LKAT, respectively.
E1099 FATTY ACID OXIDATION IN HUMAN PLACENTA
AJP-Endocrinol Metab • VOL 284 • JUNE 2003 • www.ajpendo.orgfollowed by a blocking buffer (NEN-Life Sciences, Boston,
MA) for 30 min. The blocking buffer was removed, and the
sections were exposed to primary rabbit polyclonal antisera
raised against one of the following enzymes at the indicated
dilution: MCAD (1:200), LCAD (1:400), VLCAD (1:200),
SCHAD (1:200), LCHAD (1:400), LKAT (1:400), or human
-chorionic gonadotropin (-HCG; Dako, Carpinteria, CA).
The primary antibody was applied with 0.3% Triton X-100 in
phosphate-buffered saline (PBS) overnight at 4°C. After two
washes with PBS the next day, secondary goat anti-rabbit
biotinylated antibody (NEN-Life Sciences) was applied at a
concentration of 1:800 for1ha troom temperature. The
tertiary reagent was streptavidin-horseradish peroxidase
(Dako) at a concentration of 1:1,000 for1ha troom temper-
ature followed by application of 3,3-diaminobenzidine sub-
strate for 1–5 min. The slides were rinsed, counterstained
with Mayer’s hematoxylin, dehydrated in ethanol, cleared
with xylene, and mounted with glass coverslips using Histo-
mount (Zymed Laboratories). Two to ﬁve sets of placental
tissue from term pregnancies were stained for all six FAO
enzymes.
Western blot analyses. Placental tissue freed of maternal
blood (100–250 mg) was lysed in a buffer containing 0.1 M
sodium phosphate, 0.5 mM EDTA, and 0.5% Triton with
protease inhibitors by means of a polytron. The placental
lysate was sonicated three times for 10 s each on ice. The
lysates were subjected to centrifugation at 3,000 g for 5 min,
and the protein concentration of the supernatant was mea-
sured by the Bradford method. Fifty micrograms of protein
were analyzed by immunoblotting with rabbit polyclonal
antisera raised against one of the six different FAO spiral
enzymes at the following dilutions: MCAD (1:1,000), LCAD
(1:5,000), VLCAD (1:500), SCHAD (1:5,000), LCHAD
(1:3,000), and LKAT (1:2,000). Incubation with secondary
antibody (goat anti-rabbit, 1:1,000 dilution) and visualization
with diaminobenzidine reagent were done until the protein
bands were visible. Two to ﬁve blots were prepared for each
enzyme, and a representative immunoblot was analyzed with
an AlphaImager 3400 (Alpha Innotech, San Leandro, CA)
using its AlphaEase image analysis software for densitome-
try. Densitometry data were subjected to statistical analysis
to determine any relationship of gestational age to antigen
expression.
Enzyme kinetics and metabolic ﬂux studies. The activities
of SCHAD, LCHAD, and LKAT in placental homogenates
were measured as described (3, 35, 38). Trophoblast cells
were harvested from four uncomplicated term pregnancies,
and three 75-cm2 ﬂasks from each placenta were used for
experiments. Metabolic ﬂux studies were performed using
tritiated water released from [9,10-3H]palmitate and [9,10-3H]-
myristate in 24-well microplates (22, 24). The cells were grown
for 20 h while being incubated with 22 M [9,10-3H]palmitate
or 110 M [9,10-3H]myristate, respectively. Each experiment
was run in triplicate, and in all assays, palmitic or myristic
acids were complexed with defatted bovine serum albumin (0.45
mg/ml). By use of these tritium-labeled substrates, where 3Hi s
distributed equally between two adjacent carbon atoms, 75–
100% of the label is converted to 3H2O during complete -oxi-
dation cycle in intact cytotrophoblast cells (22, 24, 36).
Statistical analyses. We made three enzyme activity mea-
surements from each sample and compared a total of 28
samples with one another after categorizing them into ges-
tational age groups; we used multivariate analysis of vari-
ance (MANOVA) with calculation of Wilk’s  and P values.
Data were later subjected to Student-Newman-Keuls post
hoc analysis for multiple comparisons using statistical soft-
ware SPSS for PC, version 11.01.
We carried out univariate and multivariate regression
analyses on densitometric data for the six FAO enzymes to
assess the signiﬁcance of regression, i.e., the relationship
between gestational age and densitometric readings. The
slope of regression was compared with zero; an R2 value, F
statistic, and signiﬁcance (P) value were calculated for each
slope. Data are presented as means  SD unless stated
otherwise; statistical signiﬁcance was set at P 	 0.05.
RESULTS
FAO pathway. Figure 1 shows the metabolic path-
way of entry of fatty acids into the cell and their
breakdown through the mitochondrial -oxidation spi-
ral. Among the six enzymes of the spiral studied here,
the highly homologous enzymes MCAD, LCAD, and
VLCAD catalyze the ﬁrst step by using substrates of
differing chain lengths. SCHAD and LCHAD, which
are also highly homologous, catalyze the second and
third reaction of the spiral, and LKAT performs the
ﬁnal cleavage step in this pathway.
Immunohistochemistry. We examined expression of
these six enzymes by immunohistochemistry in 2–5
term human placentas (Fig. 2). Minimal nonspeciﬁc
background staining was observed in control sections
processed without primary antibody (Fig. 2A). After
incubation with -HCG antibody as a positive control
(Fig. 2B), intense staining of the syncytiotrophoblast
layer was observed and, as expected, there was no
reaction in cells from the rest of chorionic villi. Figure
2, C-H, shows immunoreactivity for MCAD, SCHAD,
LKAT, VLCAD, LCAD and LCHAD, respectively. The
intensity of staining for all six enzymes was highest in
syncytiotrophoblast and similar to that of -HCG, sug-
gesting abundant expression of all FAO enzymes. No
speciﬁc immunoreactivity for any FAO enzyme was
detected in the chorionic villous vessels or connective
tissue. Although the highest levels of FAO enzyme
immunoreactivity were in the syncytiotrophoblast
layer of the chorionic villi, there was also detectable
expression of all FAO enzymes in the villous cytotro-
phoblasts. These results show abundant and cell type-
speciﬁc expression of the FAO enzymes in both syncy-
tiotrophoblast and cytotrophoblast but not in core cells
of the villi.
Expression and activity of FAO enzymes during hu-
man placental development. Figure 3 is a composite
immunoblot to analyze expression of the six FAO en-
zyme antigens in placental villi by use of specimens
from between 12 and 43 wk of gestation. Densitometric
analysis of immunoblots indicated that expression of
LCHAD, VLCAD, and SCHAD was 2- to 2.5-fold higher
at the lower gestational ages of 12 and 17 wk compared
with term placenta. LKAT expression was four- and
threefold higher at 12 and 17 wk of gestation, respec-
tively, compared with term placenta. Our multivariate
regression analysis found an inverse correlation be-
tween expression of LCHAD, SCHAD, VLCAD, and
LKAT with gestational age (R2  0.65, 0.75, 0.51, and
0.73 for LCHAD, SCHAD, VLCAD, and LKAT, respec-
tively). The slope of regression was signiﬁcantly differ-
ent from zero for LCHAD, SCHAD, VLCAD, and
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respectively. There was no measurable difference
among various gestational ages for MCAD and LCAD
expression. Figure 4 shows LCHAD, SCHAD, and
LKAT enzyme activities measured from extracts of 28
placental samples. The speciﬁc activities (nmol
min1mg tissue1) were signiﬁcantly higher for all
three enzymes at lesser gestational ages (12–28 wk)
compared with term placentas with MANOVA, with
Wilk’s  of 0.290 and P value of 0.02. Groupwise com-
parisons using the Student-Newman-Keuls test
showed a signiﬁcantly higher activity of LCHAD and
LKAT at 12–28 wk of gestation compared with term
and postterm placentas and a signiﬁcantly higher ac-
tivity of SCHAD at 12–19 wk compared with term
placentas. These results show that enzymatic activities
are regulated during the course of placental develop-
ment.
Tissue-speciﬁc activities of FAO enzymes. We com-
pared the enzyme activities of LCHAD, SCHAD,
LKAT, and CPT II in fresh, crude, placental tissue
extracts with our previously published data of activi-
ties in fresh human liver and skeletal muscle extracts
and from cultured ﬁbroblasts from normal individuals
Fig. 2. Photomicrographs of FAO en-
zyme expression in term human pla-
centa. Shown are immunohistochemi-
cal slides of placental villi from term
human placenta (originally at 
100)
stained by the peroxidase-diaminoben-
zidine method. A: negative control with
no primary antibody. Bar, 20 m. B:
positive control stained for human
-chorionic gonadotropin (-HCG) with
anti-human monoclonal antibody dem-
onstrating expression in the synctiotro-
phoblast layer (black arrows). C-H:
staining for each of the 6 FAO en-
zymes. Localization of these 6 FAO en-
zymes in term villi is similar to that of
-HCG. FAO enzymes are expressed
mainly in the synctiotrophoblast layer
(black arrows), but there is detectable,
lower expression in cytotrophoblasts
(white arrows). C: incubation with rab-
bit anti-human MCAD polyclonal anti-
body; D: with LCAD antibody; E: with
VLCAD antibody; F: with SCHAD an-
tibody; G: with LCHAD antibody; H:
with LKAT antibody.
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to ﬁvefold less than in liver throughout gestation. Com-
pared with skeletal muscle, both LCHAD and LKAT,
components of trifunctional protein that utilize long-
chain substrates, were similar or higher in placental
extracts from 12- to 19-wk-gestation pregnancies. FAO
enzyme activities in crude placental extract were com-
parable to those in cultured human ﬁbroblasts, but
freshly isolated cytotrophoblasts from term pregnan-
cies had substantially greater (2- to 8-fold) LCHAD,
SCHAD, and LKAT activities than cultured ﬁbro-
blasts. The enzyme activities in term trophoblast cells
in primary culture were two- to threefold greater than
those in fresh placental tissue from term pregnancies.
These data show that placenta contains levels of FAO
enzymes comparable to those present in mature, fatty
acid-dependent tissues such as skeletal muscle, espe-
cially between 12 and 19 wk of gestation, and that
cytotrophoblasts contain long-chain activities (LKAT
and LCHAD) comparable to those of liver.
Fatty acid ﬂux in term human cytotrophoblast cells
in culture. Table 1 shows the results of metabolic ﬂux
studies in cytotrophoblasts with tritiated palmitic acid
or myristic acid as substrates. Primary trophoblast
cells cultured for 36–48 h used the two fatty acids as
metabolic fuel, with overall oxidation of fatty acids
30–100% greater than ﬁbroblasts in culture (P 	 0.05).
DISCUSSION
Our results show that expression and activities of
FAO enzymes as well as overall FAO of palmitate and
myristate are substantial in human placental villi dur-
ing gestation and identify trophoblast components as
Fig. 3. Expression of FAO enzyme antigens in placentas of various
gestational ages. Composite Western blots were generated to assess
tissue expression of 6 FAO enzymes at gestational ages between 12
and 43 wk. Gestational ages of placentas from which protein extracts
were prepared are shown above each lane at top. Positions of migra-
tion and mass (in kDa) of protein size markers are depicted at left.
Each of the 6 panels was analyzed with antibody to the FAO enzyme
indicated at bottom right. There was expression of all 6 enzymes
throughout gestation, with greater expression at lower gestational
age for LCHAD, SCHAD, VLCAD, and LKAT.
Fig. 4. FAO enzyme activities in human placentas of various gesta-
tional ages. Pooled placentas of the gestational ages indicated in the
boxes were assayed for the 3 enzymes LCHAD (A), SCHAD (B), and
LKAT (C) indicated on the abscissas. There was a higher activity of
SCHAD, LCHAD, and LKAT at earlier gestational ages (12–28 wk)
compared with term (P 	 0.024).
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sion of FAO enzymes and measured activities at lower
gestational ages of 12–28 wk are comparable to that in
mature slow skeletal muscle, a tissue that uses fatty
acids as a substrate to satisfy high energy require-
ments. The data provide direct evidence that fatty
acids undergo extensive mitochondrial -oxidation in
the placenta. Our major conclusion is that fatty acids
are utilized as a signiﬁcant metabolic fuel and energy
source in this organ, consistent with our hypothesis.
This overall conclusion is novel and at variance with
the current concept that glucose is the sole energy
source in the placenta (14, 16). On the basis of this
conclusion, we speculate that human placental mito-
chondrial FAO is critical for normal growth and mat-
uration of the placenta and for fueling the energy-
consuming functions of ion, nutrient, and waste trans-
placental transport.
Our study’s limitations include a lack of correlation
between our in vitro data and in vivo FAO in the
fetal-placental unit and some discrepancy between our
Western blot and enzyme activity data. We are also
limited by the fact that we used term normal placenta
to extract trophoblast cells, and our metabolic ﬂux data
cannot be applied directly to trophoblast cells from
earlier gestations. Thus our in vitro data need to be
correlated with in vivo experiments, preferably in hu-
man subjects. FAO has been studied in humans by use
of 13C-labeled stable isotope technology, and a similar
study model can be applied to pregnant women to
elucidate our hypothesis more conclusively.
Our metabolic ﬂux data for palmitate and myristate
in Table 1 have high standard deviations, indicating
variability in results. Variability among primary cul-
tures is not uncommon, and trophoblast cells are no
exception. Our comparison between ﬁbroblasts, a well-
studied approach to quantiﬁcation of fatty acid oxida-
tion in humans with suspected FAO disorders, and
trophoblasts showed no statistical difference; the ma-
jor conclusion from these studies is that trophoblasts
indeed oxidize fatty acids. Because all cell lines were
cultured in media containing glucose and not in phys-
iological conditions present in vivo during fasting, we
have shown that signiﬁcant metabolic ﬂux through the
FAO pathway occurs even when glucose is the avail-
able energy substrate source. Our previous data in
ﬁbroblasts show that, when fatty acids are supplied as
substrate, expression of FAO enzymes and ﬂux
through the -oxidation pathway increases. Thus
the ﬂux measurement presented in Table 1 represents
minimal values.
Previous studies are consistent with our conclusion
that fatty acid uptake and metabolism are prominent
in placenta. Lipoprotein lipase is highly expressed on
the maternal surface of the syncytiotrophoblast and
hydrolyzes maternal plasma triacylglycerol (17, 29).
This enzyme activity would make long-chain free fatty
acids available for uptake. Maternal triglyceride levels
rise two- to threefold in late gestation, thereby increas-
ing availability of fatty acids for uptake and metabo-
lism (10, 17). Fatty acid-binding proteins that are crit-
ical for uptake of free long-chain fatty acids are also
located on the microvillous membranes of the syncy-
tiotrophoblasts facing the maternal circulation (1, 4, 5).
This location favors unidirectional ﬂow of maternal
fatty acids into the placenta. Furthermore, the VLDL/
apolipoprotein E receptor is positioned on the microvil-
lous surface in human placental trophoblast cells, con-
sistent with a role in placental lipid uptake and trans-
port (40). Perhaps most importantly, carnitine, an
essential factor for transfer of long-chain fatty acids
from the cytosol to mitochondria for subsequent -oxi-
dation, is actively transported across the placenta by
an organic cation/carnitine, sodium-dependent trans-
porter (OCTN2) that is highly expressed in placental
tissue (37). Thus previously reported results, in con-
junction with our data, strongly suggest that the hu-
man placenta is capable not only of transporting fatty
acids to the fetus but also of using them as a metabolic
fuel.
Our major conclusion has important implications for
understanding the known association of maternal liver
diseases of pregnancy, AFLP, HELLP syndrome, pla-
cental ﬂoor infarction, and preeclampsia, with LCHAD
or complete trifunctional protein deﬁciency in the fetus
(11, 13, 15, 23, 27, 32, 33, 39). We (11, 13, 23) and
others (33, 34) have shown that pregnancies carrying
an affected fetus with the missense mutation G1528C
in the -subunit of mitochondrial trifunctional protein,
a mutation that occurs in the active site of the LCHAD
enzyme, have one of these maternal complications 75%
of the time. This mutation is relatively common among
individuals of northern European ancestry (11, 33),
with a carrier frequency of 1 in 175 in the United
States and 1 in 680 in the Netherlands (8). In LCHAD
deﬁciency, accumulation of the long-chain hydroxy-
acylcarnitines, free plasma hydroxy-long-chain fatty
acids, and dicarboxylic acids occurs. These metabolites
are cytotoxic because they inhibit mitochondrial FAO
enzymes, uncouple oxidative phosphorylation, and im-
pair ATP production (7, 28, 30, 31). Long-chain acyl-
carnitines are also known to damage isolated canine
myocyte sarcolemmal membranes and potentiate free-
radical-induced lipid membrane peroxidative injury in
ischemia (21).
We previously postulated (11) that long-chain fatty
acids and their metabolites cause maternal liver dam-
age in AFLP and other maternal liver diseases. How-
ever, we were puzzled, because the source of the pos-
tulated toxic metabolites was unclear given that the
fetus does not utilize fatty acids for energy production.
The data presented here provide a likely explanation of
Table 1. Metabolic ﬂux studies in human
cytotrophoblast cells and ﬁbroblasts in culture
Tissue Palmitic Acid Myristic Acid
Fibroblast (n  34)3,35,38 23.83.0 19.02.3
Cytotrophoblast (n  4) 30.829.7 38.326.9
Data are means  SD and are expressed as pmolmin1mg
protein1 (P 	 0.05 for myristic acid). References for normative data
are shown in superscript nos.
E1103 FATTY ACID OXIDATION IN HUMAN PLACENTA
AJP-Endocrinol Metab • VOL 284 • JUNE 2003 • www.ajpendo.orgthe seemingly conﬂicting clinical ﬁndings, that is, that
the LCHAD-deﬁcient fetal-derived placenta may be the
source of these harmful metabolites, particularly as
the placental mass and energy requirements increase
substantially during the third trimester. In addition to
direct toxicity, contributing factors to maternal liver
disease might be the 50% decrease in maternal hepatic
long-chain fatty acid oxidation capacity related to ma-
ternal heterozygosity for LCHAD mutations and the
increased liberation of fatty acids during the latter
half of pregnancy due to increased lipoprotein lipase
and increased reliance on fat as an energy source by
the mother late in gestation. Thus we suggest that
the placental FAO defect causes maternal liver dis-
ease in families with LCHAD or trifunctional protein
(TFP) mutations.
A second implication of our ﬁndings is that placental
insufﬁciency due to lack of energy production in preg-
nancies with FAO-deﬁcient fetuses may occur. We (11,
13) and others (15, 27, 32, 33, 39) have noted that fetal
growth restriction and prematurity are common
among LCHAD-affected fetuses. In addition, we have
shown that ablation of the trifunctional protein -sub-
unit in mice causes intrauterine growth restriction and
perinatal lethality (12). Moreover, in VLCAD- and
LCAD-deﬁcient mice, late-gestation prenatal fetal
death is common, despite the fact that the fetus does
not rely on -oxidation for energy (Exil VJ, Sims HF,
Qin W, Roberts R, Rinaldo P, Zimmerman F, and
Strauss AW, unpublished observations; 19). These re-
sults are all consistent with the hypothesis we posed:
that placental FAO is critical for the health of the
fetal-placental-maternal unit.
Other FAO defects may also be associated with ma-
ternal liver disease but only rarely. Single case reports
of maternal liver diseases occurring during pregnan-
cies with fetuses affected by CPT I and SCAD deﬁ-
ciency exist (15, 28). Three cases of maternal liver
disease during pregnancies carrying fetuses with com-
plete trifunctional protein deﬁciency have also been
published (6). However, among families with MCAD
deﬁciency, the commonest FAO disorder, and VLCAD
deﬁciency, maternal liver diseases of pregnancy are
extremely rare. This raises the possibility that 3-hy-
droxy- and other long-chain fatty acids that must ac-
cumulate in isolated LCHAD or complete TFP deﬁcien-
cies are particularly toxic.
A second conclusion from our results is that FAO
enzymes are expressed in a cell-speciﬁc manner within
the placenta and that there is some developmental
regulation of expression during gestation. Trophoblast
cells from term placenta express key enzymes of the
-oxidation spiral, and expression was higher in the
synctiotrophoblast layer than in the cytotrophoblasts
(Fig. 2). The syncytiotrophoblast layer of chorionic villi
plays an important role in the uptake of lipids, ions,
and glucose into the placenta and their transfer to the
fetus (17, 29), functions consistent with a large en-
ergy requirement. Our measurements revealed mod-
estly higher enzyme activities at lower gestational ages
(Fig. 4), emphasizing a key role for FAO early during
gestation.
In summary, we have demonstrated the expression
and activity of six enzymes involved in the FAO -ox-
idation spiral in human placenta, with enzyme expres-
sion in a cell-speciﬁc manner localized to the syncy-
tiotrophoblast layer, with lesser activity in the cytotro-
phoblast cells, and with no expression in villous core
cells. Fatty acids are used as a major metabolic fuel by
human placentas at all gestational ages, and any de-
fect within this energy-producing pathway may ham-
per the growth, differentiation, and function of the
placenta, thereby compromising fetal growth.
Defects of FAO in the fetal-placental unit are asso-
ciated with accumulation of abnormal metabolic pre-
cursors, including hydroxyacylcarnitines and dicar-
boxylic acids. Such toxic fatty acids are likely trans-
ferred to the maternal circulation and may contribute
to the pathophysiology of preeclampsia, AFLP, and
HELLP syndrome in these families.
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